GIP and obesity disorder: At the time we started the pharmacological treatment of these patients, affected by both insulin resistance and obesity, no other GLP-1 RA or agonist of both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) with an indication for obesity treatment were available in Italy.